March 13, 2024

Q&As with Industry Leaders


Discovering the unknown: How does in silico process development change PD scientists’ work?

Jeanne Linke Northrop, BioPharm International
Nora Ketterer, Manager, Modeling Services, Cytiva

Top Tips for Successful Development of Antibody Chromatography Processes

Jeanne Linke Northrop, BioPharm International
Jakob Liderfelt, Global Product Manager, Monoclonal Antibody Polishing, Cytiva

Top challenges in recombinant protein purification process development

Jeanne Linke Northrop, BioPharm International
Emma Lind, Product Manager, Chromatography Resins, Cytiva

Optimizing your Cell Culture Process to Improve Productivity 

Jeanne Linke Northrop, Biopharm International
Mary Szorik, Senior Manager of Analytical Services, Cytiva
Alice Elwood, Analytical Services Product Manager, Cytiva

Chromatography for the Diversified Antibody Pipeline

Jeanne Linke Northrop, BioPharm International  
Eva Heldin, Section Manager of Antibody Application, R&D, Cytiva

Current Techniques and Challenges Presented in Scaling Between Bioreactors

Jeanne Linke Northrop, BioPharm International 
Andreas Castan, Strategic Technology Partnerships Leader, Cytiva

What's in Your Media? How Costly is Variability of Cell Culture Media to Your Manufacturing Process?

Megan Manzano, BioPharm International 
Christopher Woolstenhulme, Lead Analytical Scientist of Manufacturing Sciences, Cytiva

Tools and Methodologies for Smarter Downstream Process Development

Gayle S. Putrich, BioPharm International
John Scibetta, Advanced Chromatography Specialist, Cytiva

Q&A: Oligonucleotide Synthesis in Process Development and Scale-Up

Megan Manzano, BioPharm International
Greg Farlow, RNA/DNA Product Specialist, Cytiva

Using Mechanistic Modeling in Process Development for Advanced Therapeutics 

Felicity Thomas, Pharmaceutical Technology Europe
Peter Guterstam, Product Manager, Advanced Therapeutics Downstream Solutions, Cytiva
Nick Whitelock, Commercial Modeling Specialist, Cytiva

Analytical Considerations for Successful Upstream Process Development with Spivey and Lane

Chris Spivey, BioPharm International
Dr. Gregory Lane, Bristol Myers Squibb

Implementation of inline conditioning to advance process intensification

Filippo Bertoli, Senior Associate Scientist, Janssen
Séamus McHugh, Operations Manager, Janssen
Joanne Sheehy, Staff Manufacturing Process Specialist, Janssen
Sean Coomey Principal Process Engineer, Janssen
Heather Nagle, Staff Technical Operations Engineer, Janssen 

Insider Recommendations for Getting Started with Mechanistic Modeling of Chromatography

Gunnar Malmquist, Senior Principal Scientist, Cytiva
Nick Whitelock, Sales Specialist, Cytiva

Improving Productivity During Process Development and Scaling of Your Process
Andreas Castan, PhD, Strategic Technology Partnerships Leader of Business Development & Strategy, Cytiva

Anki Magnusson, Staff Research Engineer, Protein and Viral Production, Cytiva
Åsa Hagner-McWhirter, PhD, Senior Scientist, Bioprocess Applications R&D, Cytiva

Anki Magnusson, Staff Research Engineer, Protein and Viral Production, Cytiva
Åsa Hagner-McWhirter, PhD, Senior Scientist, Bioprocess Applications R&D, Cytiva

James Blackwell, President, Windshire Group, LLC  

James Blackwell, President, Windshire Group, LLC

Steven Lynn, Executive Vice-President, Pharmaceuticals, Regulatory Compliance Associates 

Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva
 
Peggy Lio, Senior Director of Global Cell Culture Services at Cytiva

Dr. Tobias Hahn, co-founder and CEO of GoSilico

Next Generation Process Chromatography
Dr. Oliver Hardick, Business Leader in the BioProcess group at Cytiva

Tools and Processes for Mature and Emerging Therapies
Rita Peters, Editorial Director of BioPharm International   
Dr. Mats Lundgren, Customer Applications Director at Cytiva

Eric Langer, President and Managing Partner at BioPlan Associates 

Dr. Neil Goss, Research and Development at CSL BioPlasma, Australia, and co-author of Production of Plasma Proteins for Therapeutic Use

Biopharma Says It Has an Evolution in New Technologies and Processes
Rita Peters, Editorial Director of BioPharm International  

Biopharmaceutical Market in Asia
Günter Jagschies, Strategic Customer Relations Leader, Cytiva
 
Techniques for Improving Process Development for Exosome-Derived Therapeutics
Aaron Noyes, Head of Downstream Processing at Codiak BioSciences 

John Curling, 3rd BioProcessing Asia Conference chair 

Jonathan Royce, Business Leader for Chromatography Resins, Cytiva

Hybrid Bioprocessing
Andrew Sinclair, President and Founder of BioPharm Services

Improvements in Protein A Chromatography
Glen Bolton, Scientific Director, Amgen

Speed and Flexibility Are Dual Goals for Biopharma Operations
Rita Peters, Editorial Director of BioPharm International 

Konstantin Konstantinov, VP Late Stage Process Development, Genzyme

Rita Peters, Editorial Director of BioPharm International   
 
Adopting Single-Use Systems
Parrish Galliher, Chief Technology Officer Upstream at Cytiva

The Evolution of the Role of CMOs in Bioprocessing

Eric Langer, President and Managing Partner at BioPlan Associates

3rd HTPD Conference
Phil Lester, Co-Organizer of the HTPD Conference

The Future of QbD, Part 1
Dr. Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi

The Future of QbD, Part 2
Dr. Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi 

Mechanistic Modeling: Does it Have a Future in Process Development?
Dr. Arne Staby, Fellow, Novo Nordisk

Continuous Chromatography: Trends, Definitions and Approaches
Dr. Karol Lacki, Customer Collaborations Leader, Cytiva

The Role of HIC in Biotech
Professor Alois Jungbauer, Department of Biotechnology, BOKU


Trends in Single-Use Technologies
Jeff Carter, Cytiva

Bioprocessing Trends and Technologies at INTERPHEX 2016
Rita Peters, Editorial Director of BioPharm International 

CMOs Embrace New Technology
Eric Langer, BioPlan Associates

Tags: process development; bioprocess development; Q&A